916 related articles for article (PubMed ID: 24076101)
1. Development of allosteric modulators of GPCRs for treatment of CNS disorders.
Nickols HH; Conn PJ
Neurobiol Dis; 2014 Jan; 61():55-71. PubMed ID: 24076101
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
[TBL] [Abstract][Full Text] [Related]
3. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.
Chen Y; Goudet C; Pin JP; Conn PJ
Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795
[TBL] [Abstract][Full Text] [Related]
4. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators.
Rodriguez AL; Nong Y; Sekaran NK; Alagille D; Tamagnan GD; Conn PJ
Mol Pharmacol; 2005 Dec; 68(6):1793-802. PubMed ID: 16155210
[TBL] [Abstract][Full Text] [Related]
5. Probing the binding site of novel selective positive allosteric modulators at the M
Khajehali E; Valant C; Jörg M; Tobin AB; Conn PJ; Lindsley CW; Sexton PM; Scammells PJ; Christopoulos A
Biochem Pharmacol; 2018 Aug; 154():243-254. PubMed ID: 29777683
[TBL] [Abstract][Full Text] [Related]
6. Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors.
Harvey BD; Siok CJ; Kiss T; Volfson D; Grimwood S; Shaffer CL; Hajós M
Neuropharmacology; 2013 Dec; 75():19-30. PubMed ID: 23831682
[TBL] [Abstract][Full Text] [Related]
7. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling.
Noetzel MJ; Gregory KJ; Vinson PN; Manka JT; Stauffer SR; Lindsley CW; Niswender CM; Xiang Z; Conn PJ
Mol Pharmacol; 2013 Apr; 83(4):835-47. PubMed ID: 23348500
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia.
Bradley SJ; Langmead CJ; Watson JM; Challiss RA
Mol Pharmacol; 2011 May; 79(5):874-85. PubMed ID: 21321061
[TBL] [Abstract][Full Text] [Related]
9. Effects of positive allosteric modulators on single-cell oscillatory Ca2+ signaling initiated by the type 5 metabotropic glutamate receptor.
Bradley SJ; Watson JM; Challiss RA
Mol Pharmacol; 2009 Dec; 76(6):1302-13. PubMed ID: 19737913
[TBL] [Abstract][Full Text] [Related]
10. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses.
Chen Y; Nong Y; Goudet C; Hemstapat K; de Paulis T; Pin JP; Conn PJ
Mol Pharmacol; 2007 May; 71(5):1389-98. PubMed ID: 17303702
[TBL] [Abstract][Full Text] [Related]
11. Metabotropic glutamate receptor 5 (mGlu
Hellyer SD; Albold S; Sengmany K; Singh J; Leach K; Gregory KJ
J Neurochem; 2019 Nov; 151(3):301-315. PubMed ID: 31376155
[TBL] [Abstract][Full Text] [Related]
12. Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias.
Arsova A; Møller TC; Hellyer SD; Vedel L; Foster SR; Hansen JL; Bräuner-Osborne H; Gregory KJ
Mol Pharmacol; 2021 May; 99(5):328-341. PubMed ID: 33602724
[TBL] [Abstract][Full Text] [Related]
13. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice.
Hikichi H; Nishino M; Fukushima M; Satow A; Maehara S; Kawamoto H; Ohta H
Eur J Pharmacol; 2010 Aug; 639(1-3):99-105. PubMed ID: 20371235
[TBL] [Abstract][Full Text] [Related]
15. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators.
Hemstapat K; de Paulis T; Chen Y; Brady AE; Grover VK; Alagille D; Tamagnan GD; Conn PJ
Mol Pharmacol; 2006 Aug; 70(2):616-26. PubMed ID: 16645124
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
Rodriguez AL; Grier MD; Jones CK; Herman EJ; Kane AS; Smith RL; Williams R; Zhou Y; Marlo JE; Days EL; Blatt TN; Jadhav S; Menon UN; Vinson PN; Rook JM; Stauffer SR; Niswender CM; Lindsley CW; Weaver CD; Conn PJ
Mol Pharmacol; 2010 Dec; 78(6):1105-23. PubMed ID: 20923853
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia.
Finlay CJ; Jackson MJ; Fisher R; Bundgaard C; Rose S; Duty S
J Parkinsons Dis; 2024; 14(2):245-259. PubMed ID: 38427500
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.
Jaeschke G; Kolczewski S; Spooren W; Vieira E; Bitter-Stoll N; Boissin P; Borroni E; Büttelmann B; Ceccarelli S; Clemann N; David B; Funk C; Guba W; Harrison A; Hartung T; Honer M; Huwyler J; Kuratli M; Niederhauser U; Pähler A; Peters JU; Petersen A; Prinssen E; Ricci A; Rueher D; Rueher M; Schneider M; Spurr P; Stoll T; Tännler D; Wichmann J; Porter RH; Wettstein JG; Lindemann L
J Med Chem; 2015 Feb; 58(3):1358-71. PubMed ID: 25565255
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
[TBL] [Abstract][Full Text] [Related]
20. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
